CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is strengthening its clinical research team ahead of launching specialized pharmaceutical and nutraceutical cannabinoid products. The company has filed 13 medical patents with the USPTO and expanded its R&D division with notable additions including Dr. Stephanie Hartmann, Dr. Yesiree Baptista, and experts in microbiology, immunology, and pharmacy. CBIH is focusing on developing mRNA vaccines for cancer and other diseases, utilizing molecular biology, nuclear medicine, and advanced technologies. The company aims to capitalize on potential cannabis reclassification from Schedule I to Schedule III and position itself as an attractive partner for larger pharmaceutical firms.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) sta rafforzando il suo team di ricerca clinica in preparazione al lancio di prodotti cannabinoidi farmaceutici e nutraceutici specializzati. L'azienda ha depositato 13 brevetti medici presso l'USPTO ed ha ampliato la sua divisione R&D con aggiunte significative tra cui la Dr.ssa Stephanie Hartmann, la Dr.ssa Yesiree Baptista e esperti in microbiologia, immunologia e farmacia. CBIH si sta concentrando sullo sviluppo di vaccini mRNA per il cancro e altre malattie, utilizzando la biologia molecolare, la medicina nucleare e tecnologie avanzate. L'azienda punta a capitalizzare sulla potenziale riclassificazione della cannabis da Tabella I a Tabella III e a posizionarsi come partner attrattivo per le grandi aziende farmaceutiche.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) está fortaleciendo su equipo de investigación clínica antes del lanzamiento de productos cannabinoides farmacéuticos y nutracéuticos especializados. La compañía ha presentado 13 patentes médicas ante la USPTO y ha expandido su división de I+D con adiciones notables que incluyen a la Dra. Stephanie Hartmann, la Dra. Yesiree Baptista y expertos en microbiología, inmunología y farmacia. CBIH se está enfocando en desarrollar vacunas de ARNm para el cáncer y otras enfermedades, utilizando biología molecular, medicina nuclear y tecnologías avanzadas. La empresa busca capitalizar la posible reclasificación de la cannabis de la Tabla I a la Tabla III y posicionarse como un socio atractivo para las grandes empresas farmacéuticas.
대마초 생명과학 국제 홀딩스(Cannabis Bioscience International Holdings, OTCMKTS: CBIH)는 전문화된 제약 및 건강 보조 식품 대마 제품 출시를 앞두고 임상 연구 팀을 강화하고 있습니다. 이 회사는 13개의 의학 특허를 USPTO에 출원했으며, 마이크로 생물학, 면역학, 약학 전문가들을 포함하여 Dr. Stephanie Hartmann, Dr. Yesiree Baptista 등의 주목할 만한 추가 인력을 통해 R&D 부서를 확장했습니다. CBIH는 암에 대한 mRNA 백신과 기타 질병을 개발하는 데 집중하고 있으며, 분자 생물학, 핵의학 및 첨단 기술을 활용하고 있습니다. 이 회사는 대마의 분류가 1급에서 3급으로 변경될 가능성을 활용하고, 대규모 제약 회사의 매력적인 파트너로 자리매김하는 것을 목표로 하고 있습니다.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) renforce son équipe de recherche clinique avant le lancement de produits cannabinoïdes pharmaceutiques et nutraceutiques spécialisés. L'entreprise a dépôsé 13 brevets médicaux auprès de l'USPTO et a élargi sa division R&D avec des ajouts notables, notamment le Dr. Stephanie Hartmann, le Dr. Yesiree Baptista et des experts en microbiologie, immunologie et pharmacie. CBIH se concentre sur le développement de vaccins à ARNm contre le cancer et d'autres maladies, utilisant la biologie moléculaire, la médecine nucléaire et des technologies avancées. L'entreprise vise à tirer parti d'une éventuelle reclassification du cannabis de la Liste I à la Liste III et à se positionner comme un partenaire attrayant pour les grandes entreprises pharmaceutiques.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) verstärkt sein klinisches Forschungsteam im Vorfeld der Einführung von spezialisierten pharmazeutischen und nutraceuticalen Cannabinoidprodukten. Das Unternehmen hat 13 medizinische Patente beim USPTO angemeldet und seine F&E-Abteilung mit bemerkenswerten Neuzugängen, darunter Dr. Stephanie Hartmann, Dr. Yesiree Baptista und Experten für Mikrobiologie, Immunologie und Pharmazie, erweitert. CBIH konzentriert sich auf die Entwicklung von mRNA-Impfstoffen gegen Krebs und andere Krankheiten und nutzt dabei Molekularbiologie, Nuklearmedizin und modernste Technologien. Das Unternehmen zielt darauf ab, von einer möglichen Neubewertung von Cannabis von der Liste I auf die Liste III zu profitieren und sich als attraktiver Partner für größere Pharmaunternehmen zu positionieren.
- Filed 13 medical patents with USPTO
- Expanded R&D team with qualified medical professionals and scientists
- Strategic positioning for potential cannabis reclassification from Schedule I to III
- Developing diversified product pipeline including mRNA vaccines
- No current product revenue or sales
- Pre-revenue stage company with ongoing R&D expenses
- Dependent on future partnerships with larger pharmaceutical firms
HOUSTON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical and nutraceutical cannabinoid products.
These initiatives are driven by CBIH's commitment to enhancing quality of life for individuals facing chronic, degenerative, and life-threatening illnesses. Moreover, the company aims to lead the future of medicine by developing innovative solutions such as mRNA vaccines for cancer and other prevalent diseases that are transforming modern medicine.
“Our mission goes beyond innovation: we aim to revolutionize the pharmaceutical industry with personalized, accessible treatments designed to significantly improve patients' quality of life. By focusing on molecular biology, nuclear medicine, genetics, and advanced technologies such as nanotechnology, picotechnology and femtotechnology, we are creating highly targeted cannabinoid-based drugs that meet the unique needs of a broader spectrum of patients,” says Rosangel Andrades, CBIH R&D Director.
As we near our product launch and continue to submit medical patents (13) to the USPTO, CBIH remains focused on strengthening our team to advance production and drive innovative research. Our goal is to position the company as an attractive partner for larger pharmaceutical firms, fostering opportunities for strategic alliances. We aim to lead the way in transformative therapeutic solutions using scientifically validated medical cannabinoids, capitalizing on the coming opportunities arising from the possible reclassification of cannabis from Schedule I to Schedule III.
Under the leadership of Dr. Andrades, our R&D division has expanded significantly, enhancing our expertise and specialized teams to drive CBIH's accelerated growth. This enhanced talent pool empowers us to establish a sustainable product sales pipeline while maintaining the highest scientific and clinical standards.
Our R&D team is proud to include Dr. Stephanie Hartmann, M.D., and Dr. Yesiree Baptista, M.D., both distinguished medical practitioners and Principal Investigators in Cannabinoid Therapies. We are also supported by Dr. Jennifer Salgueiro, Ph.D. in Microbiology, and Dr. Nancy Duarte, Ph.D. in Biology and Immunology, whose molecular science expertise is instrumental in identifying new therapeutic targets within cannabinoid research. Additionally, our formulation department is reinforced by Dr. Laura Reina, Formulation Pharmacist, Dr. Ana María Maldonado, Ph.D. in Pharmacy, and Dr. Angélica Clavijo, Master in Process Design and Management, MBA, who bring invaluable expertise to our team.
"With a team of highly qualified professionals, the company is committed to addressing critical challenges such as mental health disorders. Recognizing that these conditions can profoundly impact individuals across all demographics and acknowledging the limited efficacy and accessibility of current treatment options, we strive to pioneer innovative, science-based solutions and to expand the therapeutic landscape to those in need,” says Brian Cuban, CBIH Advisory Director.
By fortifying its team with distinguished professionals, CBIH is strategically positioned to lead in the medical cannabis retail market and reinforce its role as a pioneer in scientific and medical research. With a deep commitment to advancing cannabinoid chemistry and innovative health solutions, CBIH aims to become a dominant force in the medical cannabis industry and the premier choice in national retailers.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
FAQ
What patents has CBIH filed with the USPTO in 2024?
What is CBIH's strategy for the potential cannabis rescheduling?
Who are the key scientific team members joining CBIH's R&D division?
What types of products is CBIH developing?
